预约演示
更新于：2025-12-01
Levomefolate calcium
左甲柳叶酸钙
更新于：2025-12-01
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2009-11-23), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C20H25CaN7O6 |
InChIKeyBGJXXVMOQCHQBO-QNTKWALQSA-N |
CAS号151533-22-1 |
关联
24
项与 左甲柳叶酸钙 相关的临床试验ChiCTR2500099410
A Randomized, Controlled, Double-Blind Clinical Trial on the Efficacy and Safety of Amlodipine Folic Acid Tablets Combined with 5-Methyltetrahydrofolate Tablets in Lowering Homocysteine in Hypertensive Patients with MTHFR 677 TT Genotype
NCT06218030
PSIY-744-23: Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study
ChiCTR2400089135
A Multi-centre, Randomized, Controlled, Double-blind Clinical Study to Evaluate the Effect of 6S-5-Methyltetrahydrofolate on Immunometabolic Function and Disease Activity in Ankylosing Spondylitis
100 项与 左甲柳叶酸钙 相关的临床结果
登录后查看更多信息
100 项与 左甲柳叶酸钙 相关的转化医学
登录后查看更多信息
100 项与 左甲柳叶酸钙 相关的专利（医药）
登录后查看更多信息
598
项与 左甲柳叶酸钙 相关的文献（医药）2026-01-01FOOD AND CHEMICAL TOXICOLOGY
Preclinical safety evaluation of sodium l-methylfolate
Article
作者: Dahlberg, Sarah ; Freeman, Elaine L ; Murphy, Mary M ; Tran, Nga L ; Morris-Schaffer, Keith ; Johann, Esther
Sodium l-methylfolate (L-5-MTHF-Na; CAS Number 151533-22-1) is a source of folate proposed to be used as an alternative source of folic acid in human food. The safety of L-5-MTHF-Na was evaluated by testing for genotoxicity, and repeated dose toxicity in guideline preclinical studies. L-5-MTHF-Na was not mutagenic in the bacterial reverse mutation assay and did not induce cytogenetic effects in an in vitro chromosome aberration test and in vitro micronucleus test. In repeated dose 14-day and 90-day oral toxicity studies, rats administered up to 1000 mg/kg bw/day of L-5-MTHF-Na via oral gavage had no adverse treatment-related effects on any endpoint: clinical observations, body weights, food consumption, ophthalmic examination, neurological battery, hematology, clinical chemistry, urinalysis, tissue weights, macroscopic and microscopic observations. There was an observation of non-adverse adaptive changes in creatine kinase levels in male and female rats in the 90-day study with no tissue weight or histopathological correlate. The lack of adverse findings observed with L-5-MTHF-Na are consistent with negative findings observed in published preclinical and clinical studies on calcium l-methylfolate (L-5-MTHF-Ca). In conclusion, L-5-MTHF-Na is shown to have an overall safe profile for its use as a dietary source of folate for nutritional purposes.
2025-11-01FOOD CHEMISTRY
Folate content and stability in commercial beers: Correlations with phenolic compounds
Article
作者: Liu, Xiaozhen ; Zheng, Jinxian ; Li, Longqing ; Li, Yuting ; Jin, Mingyu ; Yu, Xiangying ; Yan, Jing-Kun ; Huang, Weiming ; Liu, Fengyuan
Folate content and stability in commercial beers were investigated using a UHPLC-Q-TOF-MS/MS method. Sixteen commercial beers from a local market contained total folate ranging from 35.0 to 199.6 μg/L, with 5-methyltetrahydrofolate (5-MTHF) as the predominant form (21-70 %). Principal component analysis revealed distinct clustering patterns among beer types and positive correlations between phenolic content and folate levels. During in vitro digestion, beers with higher phenolic content demonstrated enhanced stability of reduced folates, particularly in stout beer containing 493 mg GAE/L phenolics. Under accelerated storage (60 °C, 10 days), all samples showed significant folate degradation despite varying phenolic levels. While total phenolic content remained stable during storage, antioxidant capacity consistently declined across all samples, suggesting complex protective mechanisms beyond simple antioxidant activity. These findings provide valuable insights into folate-phenolic interactions in beer matrices and their implications for nutritional value preservation during processing and storage.
2025-11-01MOLECULAR NUTRITION & FOOD RESEARCH
Effects of a Probiotic Formulation Based on SF68, Phytosterols, and 6S‐5‐Methyltetrahydrofolic Acid on Body Composition, Biochemical Parameters, Gut Microbiota, and Gastrointestinal and General Symptoms of Overweight/Obese Subjects: The PrObesity Study
Article
作者: Fiorillo, Claudia ; Lotti, Sofia ; Cei, Francesco ; Gori, Anna Maria ; Marcucci, Rossella ; Pagliai, Giuditta ; Bertelli, Alessia ; Bertorello, Sara ; Tristan Asensi, Marta ; Amedei, Amedeo ; Giangrandi, Ilaria ; Borghi, Serena ; Bartolucci, Gianluca ; Baldi, Simone ; Becatti, Matteo ; Sofi, Francesco ; Colombini, Barbara
ABSTRACT:
Obesity and dyslipidemia are increasingly widespread. Considering gut microbiota's (GM) role in energy balance, probiotics represent a promising non‐pharmacological approach. This study assessed a probiotic formulation (SF68 + phytosterols + (6S)‐5‐methyltetrahydrofolic acid) on anthropometric, biochemical, and GM parameters, as well as gastrointestinal and general symptoms, in overweight/obese individuals with low‐to‐moderate cardiovascular risk. Forty participants (30F, mean age 51.5 ± 11 years) were randomized to receive either the probiotic or placebo daily for 12 weeks. Anthropometric data, questionnaires, and biological samples were collected pre‐ and post‐intervention. While both groups showed significant (
p
< 0.05) improvements, the probiotic group showed greater reductions in waist circumference (−1.8 cm), fat mass (−1.8 kg; −1.7%), total cholesterol (−11 mg/dL), and LDL‐cholesterol (−10.3 mg/dL), along with an increased HDL/LDL ratio (+0.1). Both probiotic and placebo resulted in a significant reduction in HbA1c (−1.7 mmol/mol and −1.5 mmol/mol, respectively). The probiotic formulation also reduced erythrocyte ROS (−29.7%), granulocyte ROS (−28.4%), and plasma nitrite/nitrate (49.5%) and significantly increased erythrocyte glutathione (GSH; +81.9%). Gastrointestinal symptoms improved, and GM analysis showed an increased Evenness index and reduced Lachnospirales abundance after probiotic treatment. These findings suggest the multi‐component probiotic formulation may support metabolic and gut health in overweight or obese individuals, although further research is warranted.
7
项与 左甲柳叶酸钙 相关的新闻（医药）
2023-08-02
100 项与 左甲柳叶酸钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膳食补充剂 | 美国 | 2009-11-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 避孕 | 临床1期 | 荷兰 | 2006-10-01 | |
| 天使综合征 | 临床前 | 美国 | 2011-12-01 | |
| 天使综合征 | 临床前 | 美国 | 2011-12-01 | |
| 天使综合征 | 临床前 | 美国 | 2011-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 47 | 齋廠遞蓋艱鹽壓餘鹹憲(獵獵簾構蓋衊鑰憲鹹繭) = 鑰鏇淵淵襯積構衊壓餘 壓齋製鹽艱糧壓膚遞繭 (壓鹽艱築鹽觸膚糧觸廠, 10.4) 更多 | - | 2017-11-14 | |||
N/A | - | 45 | Wheat rolls fortified with microencapsulated L-5-MTHF | 鏇夢衊鹹構夢構繭窪鑰(繭範憲簾夢艱構淵繭製) = 築壓窪艱廠夢壓膚艱糧 選鹹鹽壓齋積鬱製鑰壓 (網衊壓衊簾範窪鹽齋鬱 ) 更多 | - | 2013-06-01 | |
鏇夢衊鹹構夢構繭窪鑰(繭範憲簾夢艱構淵繭製) = 繭窪憲積範襯製窪糧淵 選鹹鹽壓齋積鬱製鑰壓 (網衊壓衊簾範窪鹽齋鬱 ) 更多 | |||||||
N/A | 90 | 獵範餘願鹽鹹蓋鏇膚窪(膚願鬱鑰範構鏇醖築積) = 鹽廠廠餘蓋範襯壓醖獵 遞顧獵廠齋願餘膚遞製 (壓選積窪夢鏇衊築襯鏇, 7.8) 更多 | - | 2012-09-24 | |||
(Treatment (Metafolin/Creatine/Betain/B12)) | 廠膚窪膚獵繭淵鏇膚鹹(膚鏇積窪鏇鏇積網艱蓋) = 蓋鹽網顧淵淵憲廠鹽膚 糧獵淵製願願範衊鏇簾 (壓觸網簾顧壓蓋襯鏇膚, 224.5) 更多 | ||||||
临床1期 | 44 | (EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)) | 鬱鑰範壓鹹構製夢築夢(憲蓋餘鹹膚鹽鏇積選製) = 願願廠憲積淵餘願衊鬱 繭廠鬱鑰簾鑰窪醖窪築 (簾壓遞築蓋範鹹蓋鬱衊, 鹽糧鑰淵範糧餘顧範鹹 ~ 範憲獵獵構構繭鹹繭願) 更多 | - | 2011-05-09 | ||
EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca) (EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)) | 鬱鑰範壓鹹構製夢築夢(憲蓋餘鹹膚鹽鏇積選製) = 範鑰鏇構繭蓋壓願觸膚 繭廠鬱鑰簾鑰窪醖窪築 (簾壓遞築蓋範鹹蓋鬱衊, 選壓艱鏇鬱鬱願蓋積顧 ~ 膚衊艱獵鬱網鏇築構鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用